9
views
0
recommends
+1 Recommend
4 collections
    0
    shares

      Call for Papers: Extracellular Vesicles: Broadening Horizons in Neurodegenerative Diseases

      Submit here by September 30, 2025

      About Neurodegenerative Diseases: 1.9 Impact Factor I 5.9 CiteScore I 0.648 Scimago Journal & Country Rank (SJR)

      Call for Papers: Epidemiology of CKD and its Complications

      Submit here by August 31, 2024

      About Kidney and Blood Pressure Research: 2.3 Impact Factor I 4.8 CiteScore I 0.674 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Treat COVID-19, but Not Only COVID-19: Stroke Matters as Well

      research-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          During the COVID-19 pandemic, studies reported less number of hospitalizations for acute stroke and reduction in the use of recanalization treatments. This study analyzes nationwide data on stroke admissions and management in the Czech Republic during the first wave of the COVID-19 pandemic.

          Methods

          We compared the early COVID-19 pandemic (March–May 2020) with the pre-pandemic period (January–February 2020 and March–May 2019): (a) the National Register of Reimbursed Health Services provided volume of all admissions for subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), and ischemic stroke (IS), and volume of recanalization treatments (intravenous thrombolysis [IVT] and mechanical thrombectomy [MT]); (b) Registry of Stroke Care Quality provided door-to-needle time (DNT), onset-to-door time (ODT), and stroke severity at admission (National Institutes of Health Stroke Scale, NIHSS) for IS.

          Results

          During the pandemic (March–May 2020), the peak number of COVID-19 patients treated in Czech hospitals was 39 per million. In March–May 2020 versus March–May 2019, hospital admissions decreased as follows: stroke overall by 14% ( p < 0.001), IS by 14% ( p < 0.001), SAH by 15% ( p = 0.07), and ICH by 7% ( p = 0.17). The mean age was 74 years versus 74 years ( p = 0.33), and 52% versus 51% were men ( p = 0.34). The volumes of IVT and MT decreased by 14% ( p = 0.001) and 19% ( p = 0.01), respectively. The proportions of all IS patients receiving IVT or MT remained unchanged, with, respectively, 17% versus 17% receiving IVT ( p = 0.86) and 5% versus 5% receiving MT ( p = 0.48). DNT and ODT were 24 versus 25 min ( p = 0.58) and 168 versus 156 min ( p = 0.23), respectively. NIHSS at admission did not differ (6 vs. 6; p = 0.54).

          Conclusion

          Even with a low burden of COVID-19 during the first wave and no change in organization and logistics of stroke services, stroke admissions and volume of recanalization treatments decreased. Public health communication campaigns should encourage people to seek emergency medical care for stroke symptoms during the COVID-19 pandemic.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

          The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations.
            • Record: found
            • Abstract: found
            • Article: not found

            High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

            Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection.
              • Record: found
              • Abstract: found
              • Article: not found

              Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy

              To the Editor: To address the coronavirus (Covid-19) pandemic, 1 strict social containment measures have been adopted worldwide, and health care systems have been reorganized to cope with the enormous increase in the numbers of acutely ill patients. 2,3 During this same period, some changes in the pattern of hospital admissions for other conditions have been noted. The aim of the present analysis is to investigate the rate of hospital admissions for acute coronary syndrome (ACS) during the early days of the Covid-19 outbreak. In this study, we performed a retrospective analysis of clinical and angiographic characteristics of consecutive patients who were admitted for ACS at 15 hospitals in northern Italy. All the hospitals were hubs of local networks for treatment involving primary percutaneous coronary intervention. The study period was defined as the time between the first confirmed case of Covid-19 in Italy (February 20, 2020) and March 31, 2020. We compared hospitalization rates between the study period and two control periods: a corresponding period during the previous year (February 20 to March 31, 2019) and an earlier period during the same year (January 1 to February 19, 2020). The primary outcome was the overall rate of hospital admissions for ACS. We calculated incidence rates for the primary outcome by dividing the number of cumulative admissions by the number of days for each time period. Incidence rate ratios comparing the study period with each of the control periods were calculated with the use of Poisson regression. (Details regarding the study methods are provided in the Supplementary Appendix, available with the full text of this letter at NEJM.org.) Of the 547 patients who were hospitalized for ACS during the study period, 420 (76.8%) were males; the mean (±SD) age was 68±12 years. Of these patients, 248 (45.3%) presented with ST-segment elevation myocardial infarction (STEMI). The mean admission rate for ACS during the study period was 13.3 admissions per day. This rate was significantly lower than either the rate during the earlier period in the same year (total number of admissions, 899; 18.0 admissions per day; incidence rate ratio, 0.74; 95% confidence interval [CI], 0.66 to 0.82; P<0.001) or the rate during the previous year (total number of admissions, 756; 18.9 admissions per day; incidence rate ratio, 0.70; 95% CI, 0.63 to 0.78; P<0.001). The incidence rate ratios for individual ACS subtypes are presented in Table 1. After the national lockdown was implemented on March 8, 2020, 4 a further reduction in ACS admissions was reported. (Details regarding the full secondary analyses are provided in the Supplementary Appendix.) This report shows a significant decrease in ACS-related hospitalization rates across several cardiovascular centers in northern Italy during the early days of the Covid-19 outbreak. Recent data suggest a significant increase in mortality during this period that was not fully explained by Covid-19 cases alone. 5 This observation and data from our study raise the question of whether some patients have died from ACS without seeking medical attention during the Covid-19 pandemic.

                Author and article information

                Journal
                Cerebrovasc Dis
                Cerebrovasc Dis
                CED
                Cerebrovascular Diseases (Basel, Switzerland)
                S. Karger AG (Allschwilerstrasse 10, P.O. Box · Postfach · Case postale, CH–4009, Basel, Switzerland · Schweiz · Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.com )
                1015-9770
                1421-9786
                11 August 2021
                : 1-8
                Affiliations
                [1] aDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA
                [2] bInternational Clinical Research Center, St. Anne's University Hospital, Brno, Czechia
                [3] cDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czechia
                [4] dDepartment of Neurology, St. Anne's University Hospital, Brno, Czechia
                [5] eFaculty of Medicine, Masaryk University, Brno, Czechia
                [6] fInstitute of Health Information and Statistics of the Czech Republic, Prague, Czechia
                [7] gInstitute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czechia
                [8] hDepartment of Neurology, Charles University in Prague, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czechia
                [9] iNeurological Department and Stroke Unit, Jihlava Hospital, Jihlava, Czechia
                [10] jDepartment of Neurology, University Hospital Kralovske Vinohrady and Charles University in Prague, Prague, Czechia
                Author notes
                Article
                ced-0001
                10.1159/000517968
                8450853
                34515067
                59384327-0f62-4b4f-9a54-b9207e2b0917
                Copyright © 2021 by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 4 March 2021
                : 16 June 2021
                Page count
                Figures: 3, Tables: 3, References: 25, Pages: 8
                Categories
                Clinical Research in Stroke

                Neurology
                covid-19,czech republic,intravenous thrombolysis,mechanical thrombectomy,stroke
                Neurology
                covid-19, czech republic, intravenous thrombolysis, mechanical thrombectomy, stroke

                Comments

                Comment on this article

                Related Documents Log